Search
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalMidecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on positi...
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist. Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activato...
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[L4779] It was also approved by the European Commission on January 7, 2021.[L45241]
Phenaridine
go.drugbank.com/drugs/DB09178ExperimentalIllicitFentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]
Budesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigationalBudesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval o...
Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalPhase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalAlthough Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalSARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain ...